232 related articles for article (PubMed ID: 30559259)
1. Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial.
Jäger U; D'Sa S; Schörgenhofer C; Bartko J; Derhaschnig U; Sillaber C; Jilma-Stohlawetz P; Fillitz M; Schenk T; Patou G; Panicker S; Parry GC; Gilbert JC; Jilma B
Blood; 2019 Feb; 133(9):893-901. PubMed ID: 30559259
[TBL] [Abstract][Full Text] [Related]
2. Safety, tolerability, and activity of the active C1s antibody riliprubart in cold agglutinin disease: a phase 1b study.
D'Sa S; Vos JMI; Barcellini W; Wardęcki M; Perrin L; Barker G; Zilberstein M; Storek M; Chow T; Röth A
Blood; 2024 Feb; 143(8):713-720. PubMed ID: 38085846
[TBL] [Abstract][Full Text] [Related]
3. [Sutimlimab for cold agglutinin disease, a newcomer among complement inhibitors in immunohematology].
Michel M
Rev Med Interne; 2024 May; 45(5):255-257. PubMed ID: 38719668
[No Abstract] [Full Text] [Related]
4. Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL study.
Röth A; Barcellini W; Tvedt THA; Miyakawa Y; Kuter DJ; Su J; Jiang X; Hobbs W; Arias JM; Shafer F; Weitz IC
Ann Hematol; 2022 Oct; 101(10):2169-2177. PubMed ID: 35999387
[TBL] [Abstract][Full Text] [Related]
5. The evolving management algorithm for the patient with newly diagnosed cold agglutinin disease.
Barcellini W; Fattizzo B
Expert Rev Hematol; 2024 Jun; ():1-8. PubMed ID: 38872338
[TBL] [Abstract][Full Text] [Related]
6. COVID-19 vaccine safety and immunogenicity in patients with cold agglutinin disease receiving concomitant sutimlimab.
Fattizzo B; Röth A; Broome CM; Khan U; Wardęcki M; Cordoba M; Barcellini W
Am J Hematol; 2024 Apr; 99(4):789-791. PubMed ID: 38385639
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of sutimlimab in cold agglutinin disease.
Ito S; Wang D; Purcell A; Chetlapalli K; Lee AI; Cuker A; Goshua G
Am J Hematol; 2024 May; ():. PubMed ID: 38733355
[TBL] [Abstract][Full Text] [Related]
8. Röth A, Broome CM, Barcellini W, et al. Long-term sutimlimab improves quality of life for patients with cold agglutinin disease: CARDINAL 2-year follow-up. Blood Adv. 2023;7(19):5890-5897.
Blood Adv; 2024 Jun; 8(11):2650. PubMed ID: 38809539
[No Abstract] [Full Text] [Related]
9. Antibody based therapeutics for autoimmune hemolytic anemia.
Cavallaro F; Barcellini W; Fattizzo B
Expert Opin Biol Ther; 2023; 23(12):1227-1237. PubMed ID: 37874225
[TBL] [Abstract][Full Text] [Related]
10. Controlling the complement system for prevention of red cell destruction.
Yazdanbakhsh K
Curr Opin Hematol; 2005 Mar; 12(2):117-22. PubMed ID: 15725901
[TBL] [Abstract][Full Text] [Related]
11. Organizing Pneumonia in a Case of Cold Agglutinin Disease with Pulmonary Thrombosis.
Yabuuchi Y; Minami Y; Kuroda A; Ooba N; Matsuda T; Kanazawa J; Miura Y; Usui S; O-Ishi S; Hayashihara K; Saito T; Hizawa N
Intern Med; 2024 Jun; 63(12):1801-1806. PubMed ID: 37952958
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of concurrent cold agglutinin disease and myelodysplastic syndrome.
Tabata R; Tabata C
Transfus Apher Sci; 2024 Jun; 63(3):103939. PubMed ID: 38678983
[TBL] [Abstract][Full Text] [Related]
13. Novel pharmacotherapy for drug-induced immune hemolytic anemia.
Barcellini W; Fattizzo B
Expert Opin Pharmacother; 2023; 24(18):1927-1931. PubMed ID: 38037866
[No Abstract] [Full Text] [Related]
14. Prevention of complement-mediated immune hemolysis by a small molecule compound.
Mqadmi A; Zheng X; Song J; Abramowitz S; Giclas P; Yazdanbakhsh K
Biochem Biophys Res Commun; 2004 Dec; 325(4):1465-71. PubMed ID: 15555593
[TBL] [Abstract][Full Text] [Related]
15. When you think you should transfuse…don't!
Gammon RR; Alvarez H; Masias C; Benitez N; Resto C
Lab Med; 2024 Apr; ():. PubMed ID: 38581079
[TBL] [Abstract][Full Text] [Related]
16. Cold agglutinin-induced acrocyanosis without hemolytic anemia.
Kitamura W; Kobayashi H; Iseki A; Wada H; Maeda Y; Kuyama S
Ann Hematol; 2024 Feb; 103(2):681-683. PubMed ID: 37940715
[No Abstract] [Full Text] [Related]
17. Increased risk of thrombotic events in cold agglutinin disease: A 10-year retrospective analysis.
Broome CM; Cunningham JM; Mullins M; Jiang X; Bylsma LC; Fryzek JP; Rosenthal A
Res Pract Thromb Haemost; 2020 May; 4(4):628-635. PubMed ID: 32548562
[TBL] [Abstract][Full Text] [Related]
18. Pyrites: A Case of Severe Hemolytic Anemia.
Xie Z; Li W; Chen X
J Pediatr Hematol Oncol; 2024 Apr; 46(3):175-176. PubMed ID: 38150636
[No Abstract] [Full Text] [Related]
19. Clinical and laboratory characteristics of patients with cold agglutinin disease: A retrospective analysis at a tertiary medical center.
Mehrotra H; Otrock ZK
Asian J Transfus Sci; 2023; 17(2):229-233. PubMed ID: 38274972
[TBL] [Abstract][Full Text] [Related]
20. Correction to: Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patientreported outcomes from the CARDINAL study.
Röth A; Barcellini W; Anderson Tvedt TH; Miyakawa Y; Kuter DJ; Su J; Jiang X; Hobbs W; Morales J; Shafer F; Weitz IC
Ann Hematol; 2024 May; 103(5):1803. PubMed ID: 38519606
[No Abstract] [Full Text] [Related]
[Next] [New Search]
